arrow
J

Jonas Halfvarson

orebro university
H指数:68
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study

首次对炎症性肠病家系队列研究中微生物变化的了解

2025-12-310
PRE
Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study
2025-12-150
PRE
CPa9-HNE and PRO-C6 Biomarkers Reflect Fibrostenotic Strictures and Endoscopic Disease Activity in Crohn's Disease - IBSEN III Study

CPa9-HNE和PRO-C6生物标志物反映克罗恩病中的纤维化狭窄和内镜疾病活动性——IBSEN III研究

2025-12-010
PRE
Long-term disease course of Crohn’s disease in a prospective European population-based inception cohort – an Epi-IBD cohort study

克罗恩病长期疾病进程:一项前瞻性欧洲人群为基础的发病队列研究——Epi-IBD队列研究

2025-11-030
OAAI
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials

国际共识:肠道超声在炎症性肠病试验中的应用

2025-09-011
PRE
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn’s Disease Trials and Clinical Practice

国际磁共振成像共识(用于管腔克罗恩病试验和临床实践)

2025-08-270
PRE
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

托法替布与乌帕替尼治疗急性重度溃疡性结肠炎的疗效比较

2025-07-260
OAAI
Reply

回复

2025-06-230
PRE
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review (vol 42, pg 1360, 2025)

SDZ-ADL(一种阿达木单抗生物类似药)在生物制剂初治和转换治疗的患者中治疗免疫介导性炎症性疾病的疗效、安全性和免疫原性:文献综述(卷42,页1360,2025)

2025-04-280
OA
Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort

粪便微生物组反映成人基于人群的起始队列中炎症性肠病的疾病状态和预后

2025-04-250
PRE
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis

克罗恩病永久性回肠造口术后复发的定义、诊断和处理 -- 系统评价和荟萃分析

2025-04-010
PRE